Charite Universitatsmedizin

2 results · Page 1 of 1

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Ivosidenib Plus Durvalumab and Gemcitabine/Cisplatin as First-Line Therapy in Participants With Locally Advanced or Metastatic Cholangiocarcinoma With an IDH1 Mutation	Locally Advanced, Unresectable or Metastatic Cholangiocarcinoma With an IDH1 Mutation	Recruiting	Phase 1 / Phase 2	2026-05-11		NCT06501625
Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 Systemic Treatment Regimen	Neoplasm Metastasis, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, neoplasm	Recruiting	Phase 3	2026-02-06		NCT06127407

Clinical trials